Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 24630778)

1.

Use of targeted therapies for advanced renal cell carcinoma in the Asia-Pacific region: opinion statement from China, Japan, Taiwan, Korea, and Australia.

Ye D, Eto M, Chung JS, Kimura G, Chang WC, Chang YH, Pang ST, Lee JL, Niu Y, Gurney H, Uemura H.

Clin Genitourin Cancer. 2014 Aug;12(4):225-33. doi: 10.1016/j.clgc.2014.01.007. Epub 2014 Feb 4. Review.

PMID:
24630778
2.

Targeted therapies: another option for metastatic RCC.

Hutchinson L.

Nat Rev Clin Oncol. 2013 Nov;10(11):607. doi: 10.1038/nrclinonc.2013.175. Epub 2013 Sep 24. No abstract available.

PMID:
24061041
3.

Targeted therapies and the treatment of non-clear cell renal cell carcinoma.

Bellmunt J, Dutcher J.

Ann Oncol. 2013 Jul;24(7):1730-40. doi: 10.1093/annonc/mdt152. Epub 2013 Apr 26. Review.

4.

Differentiating mTOR inhibitors in renal cell carcinoma.

Pal SK, Quinn DI.

Cancer Treat Rev. 2013 Nov;39(7):709-19. doi: 10.1016/j.ctrv.2012.12.015. Epub 2013 Feb 21. Review.

PMID:
23433636
5.

Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.

Oudard S, Elaidi RT.

Cancer Treat Rev. 2012 Dec;38(8):981-7. doi: 10.1016/j.ctrv.2011.12.009. Epub 2012 Jan 30. Review.

PMID:
22289686
6.

Targeted therapies and survival: what we can learn from studies in advanced renal cell carcinoma.

Procopio G, Verzoni E, de Braud F.

Oncology. 2013;84(1):39-42. doi: 10.1159/000342768. Epub 2012 Oct 17. No abstract available.

7.

Progress and contrasts of the development of tivozanib for therapy of kidney cancer.

Gupta S, Fishman M.

Expert Opin Pharmacother. 2011 Dec;12(18):2915-22. doi: 10.1517/14656566.2011.636032. Review. Erratum in: Expert Opin Pharmacother. 2012 Feb;13(2):291.

PMID:
22098229
8.

Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region.

Vrdoljak E, Ciuleanu T, Kharkevich G, Mardiak J, Mego M, Padrik P, Petruželka L, Purkalne G, Shparyk Y, Skrbinc B, Szczylik C, Torday L.

Expert Opin Pharmacother. 2012 Feb;13(2):159-74. doi: 10.1517/14656566.2012.647406. Epub 2011 Dec 23. Review. Erratum in: Expert Opin Pharmacother. 2012 Apr;13(5):781.

PMID:
22195646
9.

Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database.

Poprach A, Bortlíček Z, Büchler T, Melichar B, Lakomý R, Vyzula R, Brabec P, Svoboda M, Dušek L, Gregor J.

Med Oncol. 2012 Dec;29(5):3314-20. doi: 10.1007/s12032-012-0286-9. Epub 2012 Jun 30.

PMID:
22752571
10.

Systemic therapy in renal cell carcinoma: advancing paradigms.

Posadas EM, Figlin RA.

Oncology (Williston Park). 2012 Mar;26(3):290-301. Review.

11.

[Molecular targeted therapy for renal cell carcinoma and other urological cancers].

Miyake H, Fujisawa M.

Nihon Rinsho. 2010 Oct;68(10):1871-5. Review. Japanese.

PMID:
20954332
12.

Successes and limitations of targeted therapies in renal cell carcinoma.

Pracht M, Berthold D.

Prog Tumor Res. 2014;41:98-112. doi: 10.1159/000355906. Epub 2014 Feb 17. Review.

PMID:
24727990
13.

Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.

Zivi A, Cerbone L, Recine F, Sternberg CN.

Expert Opin Drug Saf. 2012 Sep;11(5):851-9. doi: 10.1517/14740338.2012.712108. Epub 2012 Aug 4. Review.

PMID:
22861374
14.

Practice and progress in kidney cancer: methodology for novel drug development.

Rini BI, Weinberg V, Small EJ.

J Urol. 2004 Jun;171(6 Pt 1):2115-21. Review.

PMID:
15126769
15.

Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response?

Bex A, Etto T, Vyth-Dreese F, Blank C, Griffioen AW.

Curr Oncol Rep. 2012 Jun;14(3):230-9. doi: 10.1007/s11912-012-0229-9. Review.

PMID:
22362358
16.

Optimizing treatment for metastatic renal cell carcinoma.

Patard JJ, Porta C, Wagstaff J, Gschwend JE.

Expert Rev Anticancer Ther. 2011 Dec;11(12):1901-11. doi: 10.1586/era.11.177. Review.

PMID:
22117157
17.

Clinical biomarkers of response in advanced renal cell carcinoma.

Ravaud A, Schmidinger M.

Ann Oncol. 2013 Dec;24(12):2935-42. doi: 10.1093/annonc/mdt288. Epub 2013 Aug 7. Review.

18.

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.

Chan HY, Grossman AB, Bukowski RM.

Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Epub 2010 Jul 8. Review.

PMID:
20623346
19.

Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers.

Castellano D, Ravaud A, Schmidinger M, De Velasco G, Vazquez F.

Cancer Treat Rev. 2013 May;39(3):230-40. doi: 10.1016/j.ctrv.2012.04.009. Epub 2012 May 28. Review.

PMID:
22647546
20.

Targeted therapies in metastatic renal cell carcinoma: overview of the past year.

Gross-Goupil M, Massard C, Ravaud A.

Curr Urol Rep. 2012 Feb;13(1):16-23. doi: 10.1007/s11934-011-0232-y. Review.

PMID:
22139625
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk